Item 7.01. Regulation FD Disclosure

On January 9, 2023, Monte Rosa Therapeutics, Inc. issued a press release titled "Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023" and provided a corporate update in conjunction with its participation at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The press release and presentation are furnished as Exhibit 99.1 and 99.2, respectively, to this Current Report on Form 8-K.

The information in this Form 8-K (including Exhibits 99.1 and 99.2) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits




99.1     J.P. Morgan Healthcare Conference presentation furnished by Monte Rosa
       Therapeutics, Inc. on January 9, 2023.
99.2     Press release issued by Monte Rosa Therapeutics, Inc. on January 9,
       2023, furnished herewith.
104    Cover Page Interactive Data File (embedded within the Inline XBRL
       document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses